The Editors’ Choice

The results of this study need to be accounted for when defining reference doses for food labeling and when advising patients about the effect of cofactors.A topical Janus kinase inhibitor in pediatric patients with atopic dermatitis Novel topical treatment options are still needed for pediatric pat...

Full description

Saved in:
Bibliographic Details
Published inJournal of allergy and clinical immunology Vol. 144; no. 6; p. 1509
Format Journal Article
LanguageEnglish
Published St. Louis Elsevier Limited 01.12.2019
Subjects
Online AccessGet full text
ISSN0091-6749
1097-6825
DOI10.1016/j.jaci.2019.10.025

Cover

More Information
Summary:The results of this study need to be accounted for when defining reference doses for food labeling and when advising patients about the effect of cofactors.A topical Janus kinase inhibitor in pediatric patients with atopic dermatitis Novel topical treatment options are still needed for pediatric patients with atopic dermatitis (AD). In this issue, Grossman et al (p 1524) analyzed longitudinal data on exacerbations in 1840 subjects (24% self-reported black) with mild-to-moderate asthma from 12 National Institutes of Health/National Heart, Lung, and Blood Institute–sponsored clinical trial cohorts, including a subset with genome-wide genetic data to estimate global percentage of African ancestry. Because the interferon response of sinonasal epithelial cells, which is critical for defense against viral infection, remains unknown, Hwang et al (p 1551) examined the expression levels of type I and III interferons and interferon-stimulated genes (ISGs) in patients with chronic rhinosinusitis.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ISSN:0091-6749
1097-6825
DOI:10.1016/j.jaci.2019.10.025